PURA TRADE ALERT - $0.15 Entry Point with Speculative-Buy Rating and Target $0.25 PPS
October 22 2018 - 9:03AM
InvestorsHub NewsWire
Dallas, TX -- October 22,
2018 -- InvestorsHub NewsWire -- Goldman Small Cap Research today
issued a TRADE ALERT for Puration, Inc. (USOTC:
PURA) (“PURA”). The trade alert is a follow up to the
in-depth research report that Goldman issued on October
10th, 2018 with a speculative BUY rating and target
price-per-share (PPS) of $0.025. Highlights of the trade
alert issued today follow:
PURA’s stock has been on a tear since our coverage initiation 2
weeks ago and we believe current prices represent a terrific entry
point. The stock reached our $0.25 price target (rising over 400%)
and investors elected to use the figure as a time to take profits,
leading it to its current close. The catalysts that drove it from
our $0.059 price have not changed and we believe that the re-
valuation of these shares will return, with PURA reaching our
target again in the near term.
PURA has the wind at its back. Sales are robust, new packaging
should take unit sales to new levels next year, the industry is
enjoying unparalleled attention, and the Company is well-positioned
to capitalize on its early-stage talks with key beverage producers
and distributors.
Don’t forget the opportunities north of the border. The Canadian
market offers sales and business development prospects in 2019
which could have a favorable impact on PURA’s positioning and
financials. Still, the current valuation tells us that activity on
this front is not being accounted for by investors.
The past 30 days trading has been remarkable. The volume weighted
average price over the past 30 days is $0.12 with over $82M worth
of stock and over 706M shares trading hands. While volume is likely
to taper off, we believe heavy interest in PURA is set to continue
for the balance of the year.
To view the original report issued October 10th, 2018 along with
disclosures and disclaimers, visit https://www.purationinc.com/goldman-research/.
To view today’s trade alerty, visit https://www.purationinc.com/trade-alert.
Puration Goldman Small Cap Research Report
Highlights
Puration, Inc. is a leading Texas-based, CBD-infused beverage
provider. The Company’s flagship product, EVERx, which was
introduced in 2017, targets the sports nutrition market. Puration
plans to introduce new beverages as well as grow its product
portfolio organically as well as through targeted acquisitions. As
of October 2018, the Company was set to spin off its cannabis
cultivation segment to focus its efforts exclusively on its
high-growth core CBD-infused beverage business.
According to Hemp Business Journal, the overall hemp-based CBD
market is forecast to grow from $820 million in 2017 to $1.9
billion in 2022 and given that the market remains fragmented,
fast-growing PURA is well positioned to capture market share very
quickly.
In the Opportunity Research update, analyst Rob Goldman discusses
the Company’s compelling positioning, exciting opportunities, and
innovative subsidiary spin-off plans.
Goldman noted, “PURA is one of the leading players in the
fast-growing CBD-infused beverage arena. In fact, Puration’s
flagship product has enjoyed 600% sales growth since its
introduction in 2017. Leveraging this growth, Puration plans to
execute M&A and introduce new beverage products. With double
the number of CBDs found in most beverages, PURA’s EVERx CBD
Infused Sports Waters reduce pain and muscle soreness.”
“Major beverage companies such as Constellation Brands, Coca-Cola
have already begun joint venture with companies in the cannabis
space or are devising their strategies. These recent events bode
well for companies like Puration which has demonstrated sales and a
strong customer base sports nutrition and fitness. To focus on its core, high-growth beverage business,
PURA announced a spin-off of its cannabis cultivation segment,
effective 10/11/18. This event could turn into a future bonus for
shareholders.”
“In our view, these shares are trading at
very low levels and offer substantial upside. A snapshot of the
current valuations of 2 publicly traded cannabis beverage peers
illustrates that PURA trades at a lower market cap, despite much
higher sales. Thus, we believe the stock could reach higher levels
as PURA executes its sales and M&A strategy.”
About Goldman Small Cap Research: Founded in 2009
by former Piper Jaffray analyst and mutual fund manager Rob
Goldman, Goldman Small Cap Research produces sponsored and
non-sponsored small cap and microcap stock research reports,
articles, stock market blogs, and popular investment
newsletters.
Goldman Small Cap Research is not in any way affiliated with
Goldman Sachs & Co.
This press release contains excerpts of our most recently published
sponsored company research report on Puration, Inc. which carries a
rating and a price target. The information used and
statements of fact made have been obtained from sources considered
reliable but we neither guarantee nor represent the completeness or
accuracy. Goldman Small Cap Research
relied solely upon information derived from Puration, Inc. (“the
Company”) authorized press releases or legal disclosures made in
its filings with the U.S. Securities and Exchange Commission
http://www.sec.gov.
Separate from the factual content of our
report about the Company, we may from time to time include our own
opinions about the Company, its business, markets and
opportunities. Any opinions we may offer about the Company are
solely our own, and are made in reliance upon our rights under the
First Amendment to the U.S. Constitution, and are provided solely
for the general opinionated discussion of our readers. Our opinions
should not be considered to be complete, precise, accurate, or
current investment advice. Statements herein may contain
forward-looking statements and are subject to significant risks and
uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article,
trading alert, corporate profile, or press release is not intended
as an offering, recommendation, or a solicitation of an offer to
buy or sell the securities mentioned or discussed is to be used for informational purposes
only. Please read all associated full disclosures,
disclaimers, and analyst background on our website before
investing. Neither Goldman Small Cap Research nor its parent is a
registered investment adviser or broker-dealer with FINRA or any
other regulatory agency. To download this research report or any of
our research, view our disclosures and disclaimers, or for more
information, visit www.goldmanresearch.com. Goldman Small Cap
Research was compensated $3500 by the Company for research and
distribution services, including the production of this press
release.
About Puration, Inc. (OTC - PURA) Puration,
Inc. is a leading Texas-based, CBD-infused beverage provider. The
Company’s flagship product, EVERx, which was introduced in 2017,
targets the sports nutrition market. Puration plans to introduce
new beverages as well as grow it product portfolio organically as
well as through targeted acquisitions. As of October 2018, the
Company was set to spin off its cannabis cultivation segment to
focus its efforts exclusively on its high-growth core CBD-infused
beverage business.
For more information, please visit: www.PurationInc.com
Disclaimer/Safe
Harbor:
This news release contains
forward-looking statements within the meaning of the Securities
Litigation Reform Act. The statements reflect the Company's current
views with respect to future events that involve risks and
uncertainties. Among others, these risks include the expectation
that any of the companies mentioned herein will achieve significant
sales, the failure to meet schedule or performance requirements of
the companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024